CN102573474A - 同工型选择性磷脂酶 d 抑制剂 - Google Patents

同工型选择性磷脂酶 d 抑制剂 Download PDF

Info

Publication number
CN102573474A
CN102573474A CN2010800423044A CN201080042304A CN102573474A CN 102573474 A CN102573474 A CN 102573474A CN 2010800423044 A CN2010800423044 A CN 2010800423044A CN 201080042304 A CN201080042304 A CN 201080042304A CN 102573474 A CN102573474 A CN 102573474A
Authority
CN
China
Prior art keywords
optionally substituted
cycloalkyl
alkyl
hydrogen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800423044A
Other languages
English (en)
Chinese (zh)
Inventor
H·亚历克斯·布朗
C·W·林德斯列
亚历克斯·G·沃特森
莎拉·A·斯科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN102573474A publication Critical patent/CN102573474A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2010800423044A 2009-07-24 2010-07-23 同工型选择性磷脂酶 d 抑制剂 Pending CN102573474A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22849209P 2009-07-24 2009-07-24
US61/228,492 2009-07-24
PCT/US2010/043045 WO2011011680A1 (en) 2009-07-24 2010-07-23 Isoform selective phospholipase d inhibitors

Publications (1)

Publication Number Publication Date
CN102573474A true CN102573474A (zh) 2012-07-11

Family

ID=43499428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800423044A Pending CN102573474A (zh) 2009-07-24 2010-07-23 同工型选择性磷脂酶 d 抑制剂

Country Status (14)

Country Link
US (1) US9127005B2 (https=)
EP (1) EP2456307B1 (https=)
JP (1) JP2013500260A (https=)
KR (1) KR20120090034A (https=)
CN (1) CN102573474A (https=)
AU (1) AU2010275526A1 (https=)
BR (1) BR112012001586A2 (https=)
CA (1) CA2768940C (https=)
IL (1) IL217720A0 (https=)
IN (1) IN2012DN01661A (https=)
MX (1) MX2012001064A (https=)
RU (1) RU2012106657A (https=)
SG (1) SG178102A1 (https=)
WO (1) WO2011011680A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127005B2 (en) 2009-07-24 2015-09-08 Vanderbilt University Isoform selective phospholipase D inhibitors
US9453017B2 (en) 2011-09-30 2016-09-27 Vanderbilt University Antiviral therapies with phospholipase D inhibitors
CN114778844A (zh) * 2022-03-07 2022-07-22 天津市肿瘤医院（天津医科大学肿瘤医院） Pld1作为评估肿瘤患者对于化疗药物敏感性的分子标志物的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015013744A2 (pt) * 2012-12-11 2017-07-11 Univ Vanderbilt método para tratar um sujeito contra infecção por hiv, composição farmacêutica, e, kit
WO2014093557A1 (en) * 2012-12-11 2014-06-19 Vanderbilt University Methods and compositions comprising akt inhibitors and/or phospholipase d inhibitors
IL317147A (en) * 2022-06-16 2025-01-01 Japan Tobacco Inc Dihydroxyoxadiazinone compound and its pharmaceutical use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1281502B1 (it) 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6187559B1 (en) 1997-08-28 2001-02-13 Novartis Ag Phospholipase D gene
EP1313498A4 (en) 2000-05-25 2004-04-21 Ben-Tsion Williger PHOSPHOLIPASE D EFFECTORS FOR THERAPY AND SCREENING
US6482829B2 (en) * 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US20060172363A1 (en) 2002-09-18 2006-08-03 Postech Foundation Peptide complexes containing phospholipase d
KR20070106690A (ko) * 2004-12-27 2007-11-05 아스트라제네카 아베 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
CN101223120A (zh) 2005-02-23 2008-07-16 杰克·L·阿比瑟 用于治疗增殖障碍的和厚朴酚衍生物
JP5026511B2 (ja) * 2006-05-18 2012-09-12 エフ．ホフマン−ラ ロシュ アーゲー アデノシンａ２ｂレセプターアンタゴニストとしてのチアゾロ−ピラミジン／ピリジン尿素誘導体
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010037081A1 (en) 2008-09-29 2010-04-01 Palatin Technologies, Inc. Melanocortin receptor-specific spiro-piperidine compounds
US9474861B2 (en) 2009-03-31 2016-10-25 Sanofi-Aventis Deutschland Gmbh Drug delivery device body
CA2764038A1 (en) 2009-05-29 2010-12-02 The Trustees Of Columiba University In The City Of New York Modulation of phospholipase d for the treatment of neurodegenerative disorders
SG178102A1 (en) 2009-07-24 2012-03-29 Univ Vanderbilt Isoform selective phospholipase d inhibitors
US9149445B2 (en) 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
CA2850597A1 (en) 2011-09-30 2013-04-04 Vanderbilt University Antiviral therapies with phospholipase d inhibitors
BR112015013744A2 (pt) 2012-12-11 2017-07-11 Univ Vanderbilt método para tratar um sujeito contra infecção por hiv, composição farmacêutica, e, kit
WO2014093557A1 (en) 2012-12-11 2014-06-19 Vanderbilt University Methods and compositions comprising akt inhibitors and/or phospholipase d inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROBERT LAVIERI ET AL.: "Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
SARAH A SCOTT ET AL.: "Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness", 《NATURE CHEMICAL BIOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127005B2 (en) 2009-07-24 2015-09-08 Vanderbilt University Isoform selective phospholipase D inhibitors
US9453017B2 (en) 2011-09-30 2016-09-27 Vanderbilt University Antiviral therapies with phospholipase D inhibitors
CN114778844A (zh) * 2022-03-07 2022-07-22 天津市肿瘤医院（天津医科大学肿瘤医院） Pld1作为评估肿瘤患者对于化疗药物敏感性的分子标志物的用途

Also Published As

Publication number Publication date
EP2456307A1 (en) 2012-05-30
CA2768940C (en) 2018-03-13
BR112012001586A2 (pt) 2015-09-01
US9127005B2 (en) 2015-09-08
IN2012DN01661A (https=) 2015-06-05
WO2011011680A1 (en) 2011-01-27
EP2456307A4 (en) 2013-01-16
KR20120090034A (ko) 2012-08-16
EP2456307B1 (en) 2016-11-02
US20120214832A1 (en) 2012-08-23
SG178102A1 (en) 2012-03-29
CA2768940A1 (en) 2011-01-27
IL217720A0 (en) 2012-03-29
AU2010275526A1 (en) 2012-03-15
MX2012001064A (es) 2012-07-17
RU2012106657A (ru) 2013-08-27
JP2013500260A (ja) 2013-01-07

Similar Documents

Publication Publication Date Title
CN116888108B (zh) 新型egfr降解剂
JP2020509004A (ja) Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
US20240299559A1 (en) Compounds that mediate protein degradation and methods of use thereof
US11161854B2 (en) Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
KR20160055190A (ko) 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물
EP3377501B1 (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
US8969389B2 (en) Substituted 6-methylnicotinamides as mGluR5 positive allosteric modulators
CN102573474A (zh) 同工型选择性磷脂酶 d 抑制剂
US12365685B2 (en) Substituted fused aromatic ring derivative, composition and use thereof
CN106795165A (zh) 咪唑并哒嗪化合物
KR20160050080A (ko) 트라이아졸로피리딘 화합물, 이의 조성물 및 사용 방법
JP2022511236A (ja) 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
EP3555091A1 (en) Ar-v7 inhibitors
EP3390402B1 (en) Therapeutic compounds, compositions and methods of use thereof
JP2021527662A (ja) Ｏｇａ阻害化合物
WO2025008059A1 (en) 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers
TW202024072A (zh) 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物
US12312329B2 (en) Aminopyrimidine compound used for inhibiting activity of protein kinase
US20240400553A1 (en) Amine based matriptase 2 inhibitors and uses thereof
WO2017123766A1 (en) Compounds and compositions for the treatment of disease
HK40088382A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40065647A (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
HK40065647B (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
CN113087724A (zh) 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
HK40076737A (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120711